Taken together, our results indicate that IKKα or IKKβ inhibition therapy might prove to be a promising approach to be validated in clinical trials, particularly using combination strategies to treat KRAS-induced lung cancer with loss of the tumor suppressor p53. Here, TP53 is linked to lung carcinoma.